TW458981B - Gemcitabine derivatives - Google Patents

Gemcitabine derivatives Download PDF

Info

Publication number
TW458981B
TW458981B TW087103708A TW87103708A TW458981B TW 458981 B TW458981 B TW 458981B TW 087103708 A TW087103708 A TW 087103708A TW 87103708 A TW87103708 A TW 87103708A TW 458981 B TW458981 B TW 458981B
Authority
TW
Taiwan
Prior art keywords
king
special product
special
ministry
cns
Prior art date
Application number
TW087103708A
Other languages
English (en)
Chinese (zh)
Inventor
Finn Myhren
Bernt Borretzen
Are Dalen
Marit Liland Sandvold
Original Assignee
Norsk Hydro As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Norsk Hydro As filed Critical Norsk Hydro As
Application granted granted Critical
Publication of TW458981B publication Critical patent/TW458981B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
TW087103708A 1997-01-24 1998-03-13 Gemcitabine derivatives TW458981B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB9701427A GB2321454A (en) 1997-01-24 1997-01-24 Gemcitabine esters and amides

Publications (1)

Publication Number Publication Date
TW458981B true TW458981B (en) 2001-10-11

Family

ID=10806509

Family Applications (1)

Application Number Title Priority Date Filing Date
TW087103708A TW458981B (en) 1997-01-24 1998-03-13 Gemcitabine derivatives

Country Status (7)

Country Link
CZ (1) CZ293245B6 (ru)
ES (1) ES2196528T3 (ru)
GB (1) GB2321454A (ru)
IL (1) IL130971A0 (ru)
RU (1) RU2194711C2 (ru)
TW (1) TW458981B (ru)
ZA (1) ZA98576B (ru)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0420722D0 (en) * 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
ATE405573T1 (de) * 2004-12-17 2008-09-15 Lilly Co Eli Amid-prodrug von gemcitabin, zusammensetzungen und verwendung damit
AU2008354754B2 (en) * 2008-04-17 2014-09-11 The Johns Hopkins University On01910. Na enhances chemotherapeutic agent activity in drug-resistant tumors
BR112015010941A2 (pt) 2012-11-13 2017-07-11 Boyen Therapeutics Inc pró-fármacos de gemcitabina e suas utilizações
CN110713502A (zh) * 2019-11-29 2020-01-21 南京科技职业学院 一种吉西他滨杂质的合成方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL89258A0 (en) * 1988-02-16 1989-09-10 Lilly Co Eli 2',3'-dideoxy-2',2'-difluoro-nucleosides
YU43193A (sh) * 1992-06-22 1997-01-08 Eli Lilly And Company 2'-deoksi-2',2'-difluoro(4-supstituisani)pirimidinski nukleozidi antivirusnog i antikancerogenog dejstva i međuproizvodi

Also Published As

Publication number Publication date
ZA98576B (en) 1998-07-23
IL130971A0 (en) 2001-01-28
RU2194711C2 (ru) 2002-12-20
GB9701427D0 (en) 1997-03-12
ES2196528T3 (es) 2003-12-16
GB2321454A (en) 1998-07-29
CZ293245B6 (cs) 2004-03-17
CZ247999A3 (cs) 1999-12-15

Similar Documents

Publication Publication Date Title
AU720451B2 (en) Gemcitabine derivatives
CN101061131B (zh) 吉西他滨衍生物纳微粒
JP5087052B2 (ja) 改良された治療剤
TW458981B (en) Gemcitabine derivatives
TW201734028A (zh) 抑制癌症及病毒之化合物
WO2011143593A1 (en) Conjugates of a lipoic acid derivative and anti-proliferation agent and medical uses thereof
JPS61197591A (ja) ヌクレオシド誘導体の製造方法
JP2004505899A (ja) ５’−デオキシ−ｎ−（置換されたオキシカルボニル）−５−フルオロシトシン及びその誘導体、その製造方法、並びに、これを有効性分として含む抗癌剤組成物
KR20080086481A (ko) 암의 치료를 위한 디옥솔란 유도체
NO318934B1 (no) Gemcitabinderivater
US20240043408A1 (en) Crystal form of fibroblast growth factor receptor inhibitor and preparation method therefor
MXPA99006790A (en) Gemcitabine derivatives
KR100730768B1 (ko) 5'-데옥시-ｎ-알킬옥시카르보닐-5-플루오로사이토신-5'-카르복실산 및 그 유도체와 이들의 제조방법
US20220347197A1 (en) Use of dnmt inhibitor
EP2258378A1 (en) Anti-tumor agent comprising cytidine derivative and carboplatin
KR20030050504A (ko) 신규5'-데옥시-ｎ-알킬옥시카르보닐-5-플루오로사이토신-5'-아미드 유도체, 그의 제조방법, 및 이를 유효성분으로포함하는 항암제
KR20030061525A (ko) 1-(4'-알키닐-β-Ｄ-에리트로노퓨라노실)-5-플루오로-Ｎ4-(알킬옥시카르보닐)-사이토신 유도체, 그의 제조방법, 및이를 유효성분으로 포함하는 항암제

Legal Events

Date Code Title Description
GD4A Issue of patent certificate for granted invention patent
MM4A Annulment or lapse of patent due to non-payment of fees